.png)
Baker Hughes Forecast, price target & analysts
Baker Hughes Target price 2025 - Analyst rating & recommendation
Baker Hughes Classifications & Recommendation:
Baker Hughes Price Target
| Target Price | $53.04 |
| Price | $47.30 |
| Potential | 12.14% |
| Number of Estimates | 22 |
| 22 Analysts have issued a price target Baker Hughes 2026 . The average Baker Hughes target price is $53.04. This is 12.14% higher than the current stock price. The highest price target is $60.90 28.75% , the lowest is $37.37 20.99% . | |
| A rating was issued by 26 analysts: 21 Analysts recommend Baker Hughes to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Baker Hughes stock has an average upside potential 2026 of 12.14% . Most analysts recommend the Baker Hughes stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2030
24 Analysts have issued a sales forecast Baker Hughes 2025 . The average Baker Hughes sales estimate is $27.4b . This is 0.67% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $28.9b 4.71% , the lowest is $26.4b 4.41% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $27.8b | 9.11% |
|---|---|---|
| 2025 | $27.4b | 1.46% |
| 2026 | $28.4b | 3.68% |
| 2027 | $30.2b | 6.14% |
| 2028 | $30.0b | 0.71% |
| 2029 | $30.6b | 2.04% |
| 2030 | $29.6b | 3.20% |
24 Analysts have issued an Baker Hughes EBITDA forecast 2025. The average Baker Hughes EBITDA estimate is $4.7b . This is 7.78% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.1b 16.63% , the lowest is $4.4b 0.00% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $4.6b | 22.04% |
|---|---|---|
| 2025 | $4.7b | 2.90% |
| 2026 | $5.1b | 8.81% |
| 2027 | $5.8b | 12.51% |
| 2028 | $5.8b | 0.17% |
| 2029 | $6.0b | 2.74% |
| 2030 | $5.7b | 4.27% |
EBITDA Margin
| 2024 | 16.50% | 11.85% |
|---|---|---|
| 2025 | 17.23% | 4.44% |
| 2026 | 18.08% | 4.93% |
| 2027 | 19.16% | 5.97% |
| 2028 | 19.33% | 0.89% |
| 2029 | 19.47% | 0.72% |
| 2030 | 19.25% | 1.13% |
25 Baker Hughes Analysts have issued a net profit forecast 2025. The average Baker Hughes net profit estimate is $2.4b . This is 21.18% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.6b 15.17% , the lowest is $2.3b 25.58% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $3.0b | 53.32% |
|---|---|---|
| 2025 | $2.4b | 19.36% |
| 2026 | $2.6b | 9.90% |
| 2027 | $3.0b | 15.39% |
| 2028 | $3.2b | 6.13% |
| 2029 | $3.4b | 4.31% |
| 2030 | $3.4b | 1.77% |
Net Margin
| 2024 | 10.70% | 40.52% |
|---|---|---|
| 2025 | 8.76% | 18.17% |
| 2026 | 9.29% | 6.05% |
| 2027 | 10.10% | 8.72% |
| 2028 | 10.79% | 6.83% |
| 2029 | 11.03% | 2.22% |
| 2030 | 11.60% | 5.17% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
25 Analysts have issued a Baker Hughes forecast for earnings per share. The average Baker Hughes EPS is $2.44 . This is 20.52% lower than earnings per share in the financial year 2024. The highest EPS forecast is $2.63 14.33% , the lowest is $2.30 25.08% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $2.98 | 56.02% |
|---|---|---|
| 2025 | $2.44 | 18.12% |
| 2026 | $2.68 | 9.84% |
| 2027 | $3.09 | 15.30% |
| 2028 | $3.28 | 6.15% |
| 2029 | $3.42 | 4.27% |
| 2030 | $3.48 | 1.75% |
P/E ratio
| Current | 15.41 | 5.61% |
|---|---|---|
| 2025 | 19.39 | 25.85% |
| 2026 | 17.65 | 8.97% |
| 2027 | 15.29 | 13.37% |
| 2028 | 14.41 | 5.76% |
| 2029 | 13.81 | 4.16% |
| 2030 | 13.57 | 1.74% |
Based on analysts' sales estimates for 2025, the Baker Hughes stock is valued at an EV/Sales of 1.76 and an P/S ratio of 1.70 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.75 | 21.53% |
|---|---|---|
| 2025 | 1.76 | 0.62% |
| 2026 | 1.70 | 3.55% |
| 2027 | 1.60 | 5.78% |
| 2028 | 1.61 | 0.71% |
| 2029 | 1.58 | 2.00% |
| 2030 | 1.63 | 3.31% |
P/S ratio
| Current | 1.69 | 28.01% |
|---|---|---|
| 2025 | 1.70 | 0.68% |
| 2026 | 1.64 | 3.55% |
| 2027 | 1.55 | 5.79% |
| 2028 | 1.56 | 0.71% |
| 2029 | 1.53 | 2.00% |
| 2030 | 1.58 | 3.30% |
Current Baker Hughes Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 16 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 08 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 06 2025 |
| Melius Research |
➜
Buy
|
Initiated | Aug 20 2025 |
| BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Jul 30 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Jul 30 2025 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Jul 30 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 16 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 08 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 06 2025 |
|
Initiated
Melius Research:
➜
Buy
|
Aug 20 2025 |
|
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Jul 30 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Jul 30 2025 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Jul 30 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
